TheNote
ViiV Healthcare reports positi... Note
GooglePlay AppStore
GSK press releases

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

Results reinforce lotivibart’s ultra long-acting potential with the trial progressing to evaluate a twice-yearly intravenous dosing interval
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-12-month-data-showing-investigational-bnab-lotivibart-n6ls-maintains-high-levels-of-viral-suppression-in-long-acting-hiv-treatment-regimen/ gsk.com
RSS Hunter RSS Hunter • Feb 25

Cookies help us deliver our Services. By using our Services or clicking I agree, you agree to our use of cookies .